Clinical trial
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
NCT00226980 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00226980 |
|---|---|
| Title | A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma |
| Official title | A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma |
| Lead sponsor | Stanford University, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Neoplasms |
| Intervention type | Drug |
| Interventions | Thalidomide, Capecitabine |
| Enrollment | 30 |
| Start date | Oct 1, 2002 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2006 |
| First posted | Sep 27, 2005 |
| Last update posted | Apr 14, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: